At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 476 enrolled
Drug / intervention
Canagliflozin 100 mg +1 moredrug
Likely dose
Canagliflozin 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Canagliflozin: Impact on Health Status, Quality of Life, and Functional Status in Heart Failure
In Brief
A Phase 3 clinical trial evaluating Canagliflozin 100 mg and Placebo for Heart Failure. Completed, enrolled 476 participants across 18 sites.
Detailed Summary
The purpose of this study is to determine the superiority of the effectiveness of canagliflozin 100 milligram (mg) daily versus placebo in participants with symptomatic heart failure (HF) in improving the overall Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score (TSS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedFeb 2020
Enrollment StartMar 2020
Primary CompletionNov 2021
TodayJul 2026
First PostedFeb 5, 2020
Enrollment StartMar 10, 2020
Primary CompletionNov 9, 2021
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 6.4 years ago
Interventions
Canagliflozin 100 mgdrug
Participants will receive 100 mg immediate-release, over-encapsulated tablets (as a capsule) orally once daily.
Placebodrug
Participants will receive matching placebo capsules orally once daily.